miRagen Therapeutics and Collaborators Identify Key Role for miR-133a as a Modulator of Skeletal Muscle Disorder

BOULDER, Colo.--(BUSINESS WIRE)--miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients’ lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that new preclinical data reveal an essential role for miR-133a in the maintenance of adult skeletal muscle structure and function. The study suggests that miR-133a is a modulator of the development of human centronuclear myopathy (CNM), a rare condition affecting skeletal muscles. The research, licensed by miRagen Therapeutics, was conducted by researchers at the University of Texas Southwestern Medical Center and Virginia Polytechnic Institute and State University. Results of the study were published today in the August issue of The Journal of Clinical Investigation.